OA07. 08 HUDSON: an open-label, multi-drug, biomarker-directed, phase II platform study in patients with NSCLC, who progressed on anti-PD (L) 1 therapy
B Besse, M Awad, P Forde, M Thomas, K Park… - Journal of Thoracic …, 2021 - jto.org
Methods Patients are enrolled into cohorts defined according to a biomarker matched profile
(Part A) or non-matched (Part B). Acquired resistance (ACQ) was defined as progression
after> 24 weeks of prior immunotherapy and primary resistance (PRI) defined as
progression≤ 24 weeks from onset of prior immunotherapy. Patients received durvalumab
in combination with: olaparib (PARPi; Module 1), danvatirsen (STAT3i; Module 2),
ceralasertib (ATRi; Module 3), oleclumab (anti-CD73 antibody; Module 5), trastuzumab …
(Part A) or non-matched (Part B). Acquired resistance (ACQ) was defined as progression
after> 24 weeks of prior immunotherapy and primary resistance (PRI) defined as
progression≤ 24 weeks from onset of prior immunotherapy. Patients received durvalumab
in combination with: olaparib (PARPi; Module 1), danvatirsen (STAT3i; Module 2),
ceralasertib (ATRi; Module 3), oleclumab (anti-CD73 antibody; Module 5), trastuzumab …